These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 15375323

  • 1. Antisense oligonucleotide treatment of inflammatory bowel diseases.
    Yacyshyn BR.
    Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
    [No Abstract] [Full Text] [Related]

  • 2. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
    [No Abstract] [Full Text] [Related]

  • 3. Antisense oligonucleotides in lung cancer.
    Pujol JL, Jacot W.
    Suppl Tumori; 2002 Mar; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract] [Full Text] [Related]

  • 4. Antiadhesion molecule therapy in inflammatory bowel disease.
    van Assche G, Rutgeerts P.
    Inflamm Bowel Dis; 2002 Jul; 8(4):291-300. PubMed ID: 12131614
    [Abstract] [Full Text] [Related]

  • 5. Alicaforsen therapy in inflammatory bowel disease.
    Barish CF.
    Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
    [Abstract] [Full Text] [Related]

  • 6. Antisense therapy in oncology: new hope for an old idea?
    Tamm I, Dörken B, Hartmann G.
    Lancet; 2001 Aug 11; 358(9280):489-97. PubMed ID: 11513935
    [Abstract] [Full Text] [Related]

  • 7. Crohn's trial shows the pros of antisense.
    Robertson D.
    Nat Biotechnol; 1997 Mar 11; 15(3):209. PubMed ID: 9062911
    [No Abstract] [Full Text] [Related]

  • 8. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT, Sitaraman S.
    Curr Opin Investig Drugs; 2001 Oct 11; 2(10):1401-6. PubMed ID: 11890355
    [Abstract] [Full Text] [Related]

  • 9. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 11; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 10. GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
    Agrawal S, Tang JY.
    Antisense Res Dev; 1992 Jun 11; 2(4):261-6. PubMed ID: 1363378
    [No Abstract] [Full Text] [Related]

  • 11. Drug treatment for Crohn's disease.
    Yacyshyn BR.
    Lancet; 1998 Aug 29; 352(9129):743. PubMed ID: 9729027
    [No Abstract] [Full Text] [Related]

  • 12. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D, Lahn M.
    Semin Oncol; 2003 Apr 29; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [Abstract] [Full Text] [Related]

  • 13. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
    Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR, ISIS 2302-CS9 Investigators.
    Gut; 2002 Jul 29; 51(1):30-6. PubMed ID: 12077088
    [Abstract] [Full Text] [Related]

  • 14. Genetic therapy for transplant vascular sclerosis.
    Bennett CF, Stepkowski SM.
    Transpl Immunol; 1997 Dec 29; 5(4):299-302. PubMed ID: 9504151
    [No Abstract] [Full Text] [Related]

  • 15. Tackling the real culprits in Crohn's disease.
    Bonn D.
    Lancet; 1998 Jun 06; 351(9117):1710. PubMed ID: 9734899
    [No Abstract] [Full Text] [Related]

  • 16. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct 06; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 17. Technology evaluation: alicaforsen (Isis).
    Gewirtz AT, Sitaraman SV.
    Curr Opin Mol Ther; 2005 Jun 06; 7(3):273-81. PubMed ID: 15977426
    [Abstract] [Full Text] [Related]

  • 18. Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates.
    González Ferreiro M, Crooke RM, Tillman L, Hardee G, Bodmeier R.
    Eur J Pharm Biopharm; 2003 Jan 06; 55(1):19-26. PubMed ID: 12551700
    [Abstract] [Full Text] [Related]

  • 19. Significant inhibitory effects of Hybridon's antisense compound on various HIV-1 replication steps in in vitro tests.
    AIDS Patient Care STDS; 1996 Dec 06; 10(6):375-6. PubMed ID: 11361558
    [No Abstract] [Full Text] [Related]

  • 20. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A.
    Mol Med Today; 1997 Aug 06; 3(8):324. PubMed ID: 9269683
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.